Evidence map›Paper›PMID 32374043›Full record

ArticleJournal of leukocyte biology2020

Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.

Agnieszka Jaracz-Ros, Guillaume Bernadat, Pasquale Cutolo, Carmen Gallego, Martin Gustavsson, Erika Cecon, Françoise Baleux, Irina Kufareva, Tracy M Handel, Françoise Bachelerie and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of leukocyte biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Agnieszka Jaracz-RosUniversité Paris-Saclay, INSERM, Inflammation, Microbiome and Immunosurveillance, Clamart, France.
Guillaume BernadatUniversité Paris-Saclay, CNRS, BioCIS, Châtenay-Malabry, France.ORCID 0000-0001-8955-0364
Pasquale CutoloUniversité Paris-Saclay, INSERM, Inflammation, Microbiome and Immunosurveillance, Clamart, France.
Carmen GallegoUniversité Paris-Saclay, INSERM, Inflammation, Microbiome and Immunosurveillance, Clamart, France.
Martin GustavssonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, Jolla, Louisiana, California, USA.ORCID 0000-0002-3015-2043
Erika CeconUniversité de Paris, Institut Cochin, CNRS, INSERM, Paris, France.
Françoise BaleuxInstitut Pasteur, Unité de Chimie des Biomolécules, Paris, France.ORCID 0000-0003-4926-1060
Irina KufarevaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, Jolla, Louisiana, California, USA.ORCID 0000-0001-9083-7039
Tracy M HandelSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, Jolla, Louisiana, California, USA.ORCID 0000-0002-2558-6138
Françoise BachelerieUniversité Paris-Saclay, INSERM, Inflammation, Microbiome and Immunosurveillance, Clamart, France.ORCID 0000-0002-0399-3277
Angélique LevoyeUniversité de Paris, PARCC, INSERM, Paris, France.ORCID 0000-0002-7125-7327
Inserm · FRCentre National de la Recherche Scientifique · FRUniversity of California San Diego · USInstitut Pasteur · FRUniversité Paris Cité · FRUniversity of Copenhagen · DK

Funding

The structural plasticity of chemokine and gp120 recognition by CCR5R01AI118985 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M, KUFAREVA, IRINA · 2015 to 2019
$2.7M
Chemokine interaction with CXCR4 and ACKR3: structure and activation mechanismsR01GM117424 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M, KUFAREVA, IRINA · 2016 to 2019
$2.2M
Computationally informed discovery of scavenging-sparing inhibitors of CC chemokine receptor 2R21AI149369 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUFAREVA, IRINA · 2020 to 2021
$434k
NIAID NIH HHS R01 AI118985NIAID NIH HHS R21 AI149369NIGMS NIH HHS R01 GM117424
6 · The paper itself

Abstract

Chemokines play critical roles in numerous physiologic and pathologic processes through their action on seven-transmembrane (TM) receptors. The N-terminal domain of chemokines, which is a key determinant of signaling via its binding within a pocket formed by receptors' TM helices, can be the target of proteolytic processing. An illustrative case of this regulatory mechanism is the natural processing of CXCL12 that generates chemokine variants lacking the first two N-terminal residues. Whereas such truncated variants behave as antagonists of CXCR4, the canonical G protein-coupled receptor of CXCL12, they are agonists of the atypical chemokine receptor 3 (ACKR3/CXCR7), suggesting the implication of different structural determinants in the complexes formed between CXCL12 and its two receptors. Recent analyses have suggested that the CXCL12 N-terminus first engages the TM helices of ACKR3 followed by the receptor N-terminus wrapping around the chemokine core. Here we investigated the first stage of ACKR3-CXCL12 interactions by comparing the activity of substituted or N-terminally truncated variants of CXCL12 toward CXCR4 and ACKR3. We showed that modification of the first two N-terminal residues of the chemokine (K1R or P2G) does not alter the ability of CXCL12 to activate ACKR3. Our results also identified the K1R variant as a G protein-biased agonist of CXCR4. Comparative molecular dynamics simulations of the complexes formed by ACKR3 either with CXCL12 or with the P2G variant identified interactions between the N-terminal 2-4 residues of CXCL12 and a pocket formed by receptor's TM helices 2, 6, and 7 as critical determinants for ACKR3 activation.

Indexed as

Amino Acid SequenceBenzylaminesbeta-ArrestinsBinding SitesChemokine CXCL11Chemokine CXCL12CyclamsCyclic AMPGene ExpressionHEK293 CellsHeterocyclic CompoundsHumansMolecular Dynamics SimulationMutationOligopeptidesProtein BindingACKR3 protein, humanBenzylaminesbeta-ArrestinsChemokine CXCL11Chemokine CXCL12CXCL11 protein, humanCXCL12 protein, humanCXCR4 protein, humanCyclamsCyclic AMPHeterocyclic CompoundsOligopeptidesplerixaforReceptors, CXCRReceptors, CXCR4Recombinant ProteinsT134 peptideACKR3chemokine variantsCXCL12CXCR4GPCR signalingpluridimensional efficacy

Identifiers

PMID32374043
PMCPMC7540625
OpenAlexW3022774054

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.